Abstract
The enhanced accumulation of doxorubicin by agents known to reverse multidrug resistance provides a good functional test for evaluating modulating activity. In the present study, the non-steroidal triphenylethylene toremifene selectively increased doxorubicin accumulation in multidrug resistant estrogen receptor negative MDA A-1 human breast cells compared to the MDA 231 wild type cells. MDA A-1 cells were noted to be 1,000 fold resistant to doxorubicin (IC 50=< 0.1μg/ml MDA 231; IC 50=100μg/ml MDA A-1). Total accumulation of doxorubicin, expressed as area under the time concentration curve (AUC), was increased significantly in doxorubicin resistant cells (156% increase) versus wild type MDA 231 cells (6% increase). Correction of the accumulation defect to doxorubicin in drug resistant cells required a 18–20 hour pre-incubation with toremifene. The effects of toremifene on cell cycle in MDA A-1 cells was analyzed by flow cytometric techniques. Toremifene had a dose response relationship in blocking cells in G0–G1 reducing the number of cells entering S phase of the cell cycle. This effect was maximal at concentrations which increased the accumulation of doxorubicin in MDA A-1 cells. Several metabolites of toremifene were also noted to increase doxorubicin accumulation in MDA A-1 doxorubicin resistant cells. Tore XVIII (deaminocarboxytoremifene), Tore IV (4-hydroxy-N-desmethyltoremifene) and N-desmethyltoremifene all increased the accumulation of doxorubicin significantly (114%, 128% and 42% respectively). Finally, we show evidence that toremifene and its active metabolites are present in high concentrations in human plasma following a single 200 mg oral dose. Toremifene remains a very promising agent for modulating doxorubicin cytotoxicity in multidrug resistance.
Similar content being viewed by others
References
Gerlach JH, Kartner N, Bell DR, Ling V: Multidrug resistance. Cancer Surv 5:25–46, 1986
Cornwell MM, Gottesman MM, Pastan I: Increased vin-blastine binding to membrane vesicles from multidrug resistant KB cells. J Biol Chem 261:7921–7928, 1986
Tsuruo T, Iida H, Tsukagoshi S,et al.: Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42:4730–4733, 1982
Ramu A, Fuks Z, Gatt S,et al.: Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate. Cancer Res 44:144–148, 1984
Slater LM, Sweet P, Stupecky M,et al.: Cyclosporine A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54:235–238, 1986
Inaba M, Nagashima K, Sakurai Y,et al.: Reversal of multidrug resistance by non-antitumor anthracycline analogs. Gann 75:1049–1052, 1984
Zamora JM, Pearce HL, Beck WT: Physical-chemical properties shared by compounds that modulate multiple drug resistance in human leukemia cells. Mol Pharmacol 33:454–462, 1988
DeGregorio MW, Ford JM, Benz CC, Wiebe VJ: Toremifene: Pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7:1359–1364, 1989
DeGregorio MW, Carrera CJ, Klock JC, Wilbur JR: Uptake and metabolism of doxorubicin by human leukemia cells. Cancer Chemother Pharmacol 10:29–32, 1982
Krishan A: Rapid flow cytofluorometric analysis of mam-malian cell cycle by propidium iodide staining. J Cell Biol 66:188–195, 1975
Gottesman MM, Pastan I: Clinical trials of agents that reverse multidrug resistance. J Clin Oncol 7:409–411, 1989
Chabner BA, Fojo A: Multidrug resistance: P-glycoprotein and its allies, the elusive foes. J Natl Cancer Inst 81:910–913, 1989
O'Brian CA, Liskamp RM, Solomon DH,et al.: Triphenylethylenes: A new class of protein kinase C inhibitors. JNCI 76:1243–1246, 1986
Lam PH: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118:27–32, 1984
Ramu A, Shan TC, Glaubiger D: Enhancement of doxorubicin and vinblastine sensitivity in antracycline-resistant P-388 cells. Cancer Treat Rep 67:895–899, 1983
Bellamy WT, Dalton WS, Kaily JM, Gleason MD, McCloskey TM, Dorr RT, Alberts DS: Verapamil reversal of doxorubicin resistance in multidrug resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 48:6365–6370, 1988
Baker J, Wiebe V, Koester S, Emshoff V, Lindberg M, Wurz G, DeGregorio M: Toremifene enhances doxorubicin accumulation, inhibits protein kinase C activity, increases PKC message and enhances cytotoxicity in a tumor-bearing multidrug resistant nude mouse model. Proceed Amer Can Soc, Mar, 1992
Ramu A: Structure activity relationship of compounds that restore sensitivity to doxorubicin in drug-resistant P388 cells. In: D Kessel (ed) Resistance to Antineoplastic Drugs. CRC press, Inc. Boca Raton Florida 1989, pp. 64–78
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wiebe, V., Koester, S., Lindberg, M. et al. Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells. Invest New Drugs 10, 63–71 (1992). https://doi.org/10.1007/BF00873119
Issue Date:
DOI: https://doi.org/10.1007/BF00873119